Quarterly ResultMay 7, 2026, 07:37 AM
Monte Rosa Q1 Net Loss $44.5M; Revenue Down; $324.3M Offering
AI Summary
Monte Rosa Therapeutics reported a net loss of $44.5 million for the first quarter of 2026, a significant decline from the net income of $46.9 million in the same period last year. This was primarily driven by a sharp decrease in collaboration revenue to $4.2 million from $84.9 million year-over-year, despite an increase in research and development expenses. The company bolstered its liquidity with $324.3 million in net proceeds from an underwritten public offering, bringing its total cash, cash equivalents, and marketable securities to $666.2 million as of March 31, 2026, which is expected to fund operations for at least 12 months.
Key Highlights
- Net loss was $44.5 million for Q1 2026, compared to net income of $46.9 million in Q1 2025.
- Collaboration revenue decreased significantly to $4.2 million in Q1 2026 from $84.9 million in Q1 2025.
- Basic loss per share was $0.45 in Q1 2026, compared to earnings per share of $0.57 in Q1 2025.
- Research and development expenses increased to $44.1 million in Q1 2026 from $32.2 million in Q1 2025.
- Proceeds from an underwritten public offering, net of commissions, totaled $324.3 million in Q1 2026.
- Cash, cash equivalents, and marketable securities stood at $666.2 million as of March 31, 2026.
- Received $16.0 million in preclinical milestones and $3.0 million for target replacement options from Roche.
Price Impact
More from GLUE